Actively Recruiting
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
Led by Peking Union Medical College Hospital · Updated on 2026-04-07
60
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with superficial organ involvement: prednisone plus iguratimod and prednisone plus leflunomide.
CONDITIONS
Official Title
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fulfillment of the 2019 American College of Rheumatology/European League against Rheumatology (ACR/EULAR) IgG4-related disease classification criteria
- Newly-onset or relapsed IgG4-RD patients requiring initiation or continuation of glucocorticoid treatment
- Patients starting glucocorticoid treatment at less than 10 mg per day
You will not qualify if you...
- Diagnosis of other autoimmune diseases
- Diagnosis of malignant diseases
- Pregnant or breastfeeding women
- Active infections such as HIV, HCV, HBV, or tuberculosis
- Severe irreversible organ damage
- Use of biologic therapy or immunosuppressive agents other than glucocorticoids
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
Y
Yunyun Fei, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here